Dublin, April 21, 2026 (GLOBE NEWSWIRE)-- The "Cone Rod Dystrophy Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global cone rod dystrophy market is witnessing ...
For mere clinical classification purposes, rod-cone dystrophies can be broadly divided into early onset forms (i.e., which are either consistently severe from birth with little progression thereafter ...
Bayer AG and its wholly owned, independently operated subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company announced that its investigational cell therapy, lemiretprocel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results